Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,769
archived clinical trials in
Migraine Headaches

Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
University of South Carolina
mi
from
Columbia, SC
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
University of South Carolina
mi
from
Columbia, SC
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Coastal Carolina Research Center
mi
from
Mount Pleasant, SC
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Coastal Carolina Research Center
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
BG Neurology
mi
from
Spartanburg, SC
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
BG Neurology
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
ClinSearch, LLC
mi
from
Chattanooga, TN
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
ClinSearch, LLC
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
FutureSearch Trials of Neurology and Sleep Lab
mi
from
Austin, TX
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
FutureSearch Trials of Neurology and Sleep Lab
mi
from
Austin, TX
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Headache Medicine Specialist of North Texas
mi
from
Dallas, TX
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Headache Medicine Specialist of North Texas
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Foothill Family Clinic
mi
from
Salt Lake City, UT
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Foothill Family Clinic
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Sentara Neurology Specialists
mi
from
Virginia Beach, VA
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Sentara Neurology Specialists
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Northwest Clinical Research Center
mi
from
Bellevue, WA
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Northwest Clinical Research Center
mi
from
Bellevue, WA
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Premier Clinical Research
mi
from
Spokane, WA
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Premier Clinical Research
mi
from
Spokane, WA
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Dean Foundation For Health Research & Education
mi
from
Middleton, WI
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Dean Foundation For Health Research & Education
mi
from
Middleton, WI
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Healthcare Research Network - Hazelwood
mi
from
Hazelwood, MO
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Healthcare Research Network - Hazelwood
mi
from
Hazelwood, MO
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Health Research of Hampton Roads
mi
from
Newport News, VA
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Health Research of Hampton Roads
mi
from
Newport News, VA
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Preferred Primary Care Physicians
mi
from
Pleasant Hills, PA
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Preferred Primary Care Physicians
mi
from
Pleasant Hills, PA
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
mi
from
Buenos Aires,
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
mi
from
Buenos Aires,
Click here to add this to my saved trials
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated:  12/31/1969
Christie Clinic
mi
from
Champaign, IL
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status: Enrolling
Updated: 12/31/1969
Christie Clinic
mi
from
Champaign, IL
Click here to add this to my saved trials
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated:  12/31/1969
California Medical Clinic for Headache
mi
from
Santa Monica, CA
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated: 12/31/1969
California Medical Clinic for Headache
mi
from
Santa Monica, CA
Click here to add this to my saved trials
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated:  12/31/1969
Encompass Clinical Research
mi
from
Spring Valley, CA
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated: 12/31/1969
Encompass Clinical Research
mi
from
Spring Valley, CA
Click here to add this to my saved trials
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated:  12/31/1969
New England Institute for Clinical Research
mi
from
Stamford, CT
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated: 12/31/1969
New England Institute for Clinical Research
mi
from
Stamford, CT
Click here to add this to my saved trials
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated:  12/31/1969
Sunrise Clinical Research, Inc.
mi
from
Hollywood, FL
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated: 12/31/1969
Sunrise Clinical Research, Inc.
mi
from
Hollywood, FL
Click here to add this to my saved trials
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated:  12/31/1969
Jacksonville Center for Clinical Research
mi
from
Jacksonville, FL
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated: 12/31/1969
Jacksonville Center for Clinical Research
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated:  12/31/1969
Mercy Health Research
mi
from
Saint Louis, MO
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated: 12/31/1969
Mercy Health Research
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated:  12/31/1969
Albuquerque Neurosciences
mi
from
Albuquerque, NM
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated: 12/31/1969
Albuquerque Neurosciences
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated:  12/31/1969
Pharmquest
mi
from
Greensboro, NC
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated: 12/31/1969
Pharmquest
mi
from
Greensboro, NC
Click here to add this to my saved trials
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated:  12/31/1969
Wilmington Health Associates
mi
from
Wilmington, NC
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated: 12/31/1969
Wilmington Health Associates
mi
from
Wilmington, NC
Click here to add this to my saved trials
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated:  12/31/1969
Suburban Research Associates
mi
from
Media, PA
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated: 12/31/1969
Suburban Research Associates
mi
from
Media, PA
Click here to add this to my saved trials
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated:  12/31/1969
Clinpoint Trial, LLC
mi
from
Waxahachie, TX
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated: 12/31/1969
Clinpoint Trial, LLC
mi
from
Waxahachie, TX
Click here to add this to my saved trials
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated:  12/31/1969
Ericksen Research And Development
mi
from
Clinton, UT
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated: 12/31/1969
Ericksen Research And Development
mi
from
Clinton, UT
Click here to add this to my saved trials
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated:  12/31/1969
Blue Ridge Research Center
mi
from
Roanoke, VA
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated: 12/31/1969
Blue Ridge Research Center
mi
from
Roanoke, VA
Click here to add this to my saved trials
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated:  12/31/1969
Investigational Site Number 056004
mi
from
Brugge,
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status: Enrolling
Updated: 12/31/1969
Investigational Site Number 056004
mi
from
Brugge,
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Birmingham, AL
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13568
mi
from
Encino, CA
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13568
mi
from
Encino, CA
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1326
mi
from
Fullerton, CA
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1326
mi
from
Fullerton, CA
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10147
mi
from
Long Beach, CA
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10147
mi
from
Long Beach, CA
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13571
mi
from
Redondo Beach, CA
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13571
mi
from
Redondo Beach, CA
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
San Diego, CA
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10271
mi
from
Santa Monica, CA
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10271
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1344
mi
from
Boulder, CO
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1344
mi
from
Boulder, CO
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13563
mi
from
East Hartford, CT
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13563
mi
from
East Hartford, CT
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 11141
mi
from
Hialeah, FL
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 11141
mi
from
Hialeah, FL
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 021
mi
from
Jacksonville, FL
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 021
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10269
mi
from
Orlando, FL
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10269
mi
from
Orlando, FL
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13567
mi
from
Palm Beach Gardens, FL
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13567
mi
from
Palm Beach Gardens, FL
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site ZEIG
mi
from
Pembroke Pines, FL
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site ZEIG
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 096
mi
from
Atlanta, GA
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 096
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Louisville, KY
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Louisville, KY
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 603
mi
from
Watertown, MA
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 603
mi
from
Watertown, MA
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 098
mi
from
Ann Arbor, MI
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 098
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 39
mi
from
Golden Valley, MN
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 39
mi
from
Golden Valley, MN
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13534
mi
from
Kansas City, MO
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13534
mi
from
Kansas City, MO
Click here to add this to my saved trials